ReviewDiabetologia2022
Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time.
Review in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches.Diabetologia · 2026Review
- Exploring Treatment Paradigms in Type 2 Diabetes: A Comparison of Independent and Combined Therapeutic Approaches.Cureus · 2026Review
- Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes.Diabetologia · 2026Review
- Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?Obesity (Silver Spring, Md.) · 2025Review
- The influence of hypertensive disorders of pregnancy on the development of long-term postpartum type 2 diabetes mellitus.Endocrine journal · 2025Article
- Comparison of polygenic risk scores for type 2 diabetes developed from different ancestry groups.npj metabolic health and disease · 2025Article
- Mapping the state-of-the-art of the barriers for personalized preventive approaches worldwide: A scoping review of reviews.PloS one · 2025Article
- Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes.Frontiers in endocrinology · 2025Review
- Sleep patterns in adults and children with less common forms of diabetes.Frontiers in endocrinology · 2025Review
- Interaction effect between low birthweight and resistin gene rs1862513 variant on insulin resistance and type 2 diabetes mellitus in adulthood: Toon Genome Study.Journal of diabetes investigation · 2024Article
- The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects-A Family Doctor Perspective.Journal of clinical medicine · 2024Review
- Multimodal digital phenotyping of diet, physical activity, and glycemia in Hispanic/Latino adults with or at risk of type 2 diabetes.NPJ digital medicine · 2024Article
- A scoping review of artificial intelligence-based methods for diabetes risk prediction.NPJ digital medicine · 2023Article
- Toward better diabetes care: Exploration and implementation.Journal of diabetes investigation · 2023Review
- Using Continuous Glucose Monitoring to Prescribe a Time to Exercise for Individuals with Type 2 Diabetes.Journal of clinical medicine · 2023Article
- The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond.Journal of the Indian Institute of Science · 2023Review
- Konjac Glucomannan: An Emerging Specialty Medical Food to Aid in the Treatment of Type 2 Diabetes Mellitus.Foods (Basel, Switzerland) · 2023Review
- Precision Medicine in Type 1 Diabetes.Journal of the Indian Institute of Science · 2023Review
- Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Genomic discoveries unveil mechanistic insights in diabetes.Cell genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Rapid advances in technology and data science have the potential to improve the precision of preventive and therapeutic interventions, and enable the right treatment to be recommended, at the right time, to the right person. There are well-described examples of successful precision medicine approaches for monogenic conditions such as specific diets for phenylketonuria, and sulfonylurea treatments for certain types of MODY. However, the majority of chronic diseases are polygenic, and it is unlikely that the research strategies used for monogenic diseases will deliver similar changes to practice for polygenic traits. Type 2 diabetes, for example, is a multifactorial, heterogeneous, polygenic palette of metabolic disorders. In this non-systematic review I highlight limitations of the evidence, and the challenges that need to be overcome prior to implementation of precision medicine in the prevention and management of type 2 diabetes. Most precision medicine approaches are spuriously precise, overly complex and too narrowly focused on predicting blood glucose levels with a limited set of characteristics of individuals rather than the whole person and their context. Overall, the evidence to date is insufficient to justify widespread implementation of precision medicine approaches into routine clinical practice for type 2 diabetes. We need to retain a degree of humility and healthy scepticism when evaluating novel strategies, and to demand that existing evidence thresholds are exceeded prior to implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.